News by region

Inflazome Receives Funding from The Michael J. Fox Foundation for Parkinson’s Research

Funding in excess of US$1 million to support the development of a brain imaging probe for patient diagnosis and the

Posted in Europe, news | Tagged , | Leave a comment

Axcella Appoints Shreeram Aradhye, M.B.B.S., M.D., as Executive Vice President, Chief Development Officer

CAMBRIDGE, Mass.–(BUSINESS WIRE)—-Axcella Health, a biotechnology company pioneering the research and development of novel multifactorial interventions to address dysregulated metabolism

Posted in news, North America | Tagged | Leave a comment

City of Hope Study Finds Popular Diabetes Diagnosis Test Misses Most Cases

The study was presented at ENDO 2019, Endocrine Society’s annual meeting DUARTE, Calif.–(BUSINESS WIRE)–lt;a href=”https://twitter.com/hashtag/CityofHope?src=hash” target=”_blank”gt;#CityofHopelt;/agt;–The hemoglobin A1c blood test

Posted in news, North America | Tagged | Leave a comment

Gossamer Bio Announces 2018 Annual Financial Results

SAN DIEGO–(BUSINESS WIRE)–Gossamer Bio, Inc. (Nasdaq:GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the

Posted in news, North America | Tagged , | Leave a comment

Teva Announces Launch of a Generic Version of EXJADE® (deferasirox) Tablets For Oral Suspension in the United States

JERUSALEM–(BUSINESS WIRE)–Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of EXJADE®1 (deferasirox)

Posted in Middle East and North Africa, news, North America | Tagged | Leave a comment

Cerveau Technologies Inc. Signs Research Agreement with Eisai Inc., for Novel Tau Imaging Agent

BOSTON–(BUSINESS WIRE)–Cerveau Technologies, Inc. today announced a research collaboration agreement with Eisai Inc., which will enable Eisai to use Cerveau’s

Posted in Asia, news, North America | Tagged , | Leave a comment

Eisai, Biogen kick-off phase 3 testing early Alzheimer’s disease antibody, amid dropping aducanunab trial. Eisai’s US company presents AD pipeline

Eisai Co said Friday thata global Phase III clinical study (Clarity AD/Study 301) of BAN2401, an anti-amyloid beta protofibril antibody, in patients with early Alzheimer’s disease has been initiated.

Posted in Approval, Asia, Europe, North America, Regions | Tagged , , | Leave a comment

Neurotrope jumps in the Alzheimer’s solution chase, amid Biogen’s, Eisai’s dropping aducanunab trial

Neurotrope said Friday, commenting Biogen Inc.’s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer’s disease, Phase 2 clinical trial using its drug Bryostatin during the second half of 2019.

Posted in news, North America | Tagged , , , , , | Leave a comment

ProMIS offeri potential significant advantage over aducanumab, learns from mistakes

ProMIS Neurosciencesissued a pres release Friday, raising urgency to selectively target the toxic oligomer with exacting precision as part of the global effort to develop disease-modifying therapies for Alzheimer’s disease (AD), upon Biogen’s and Eisai’s dropping two alte-stage clinical trials of aducanumab.

Posted in Approval, North America | Tagged , , , , | Leave a comment

Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer ST.

Posted in news, North America | Tagged , , | Leave a comment